The STent Or NEphrostomy Study: A Randomised Controlled Trial Evaluating the Effectiveness of Percutaneous Nephrostomy Versus Internal Stent in Patient with Urolithiasis and an Indication for Decompression [0.03%]
支架组还是肾造瘘组研究：一项关于泌尿系结石减压的随机对照试验评估经皮肾穿刺造瘘与内支架效果的研究
Nora Hendriks,Hugo W Schuil,Ruben G Duijnhoven et al.
Nora Hendriks et al.
Background and objective: Obstruction by urolithiasis may be the reason for a percutaneous nephrostomy (PCN) or the placement of an internal stent. High-quality evidence is scarce. The objective of this study is to invest...
Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study [0.03%]
一项关于TRANSLATE研究的成本效益性：局部麻醉经会阴与经直肠活检的比较
Matthew Little,Jane Wolstenholme,Filipa Landeiro et al.
Matthew Little et al.
Background and objective: A local anaesthetic ultrasound-guided transperineal (LATP) prostate biopsy has advantages over transrectal ultrasound (TRUS)-guided biopsy, with improved magnetic resonance imaging (MRI)-guided p...
Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis [0.03%]
转移性激素敏感性前列腺癌治疗对健康相关生活质量的影响：系统评价和网络 meta 分析
Tessa van Elst,Pedro Lopez,Laurien M Buffart et al.
Tessa van Elst et al.
Background and objective: In metastatic hormone-sensitive prostate cancer (mHSPC), health-related quality of life (HRQoL) is key for personalised treatment decisions. We compared the impact of different mHSPC treatment st...
Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer-Oncological Outcome from Long-term Follow-up [0.03%]
挽救性淋巴结清扫治疗前列腺癌盆腔淋巴结复发的长期随访结果分析
Ruth Himmelsbach,Simon K B Spohn,Anca-Ligia Grosu et al.
Ruth Himmelsbach et al.
Background and objective: Salvage lymph node dissection (sLND) in recurrent prostate cancer (PC) is still considered experimental due to limited prospective data and sparse long-term outcome reports. This study describes ...
Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial [0.03%]
基于ANZUP1901试验的转移性去势抵抗性前列腺癌患者PSMA靶向放射配体治疗的时间依赖性治疗效应
Wei Chen,Soichiro Yoshida,Koichiro Kimura et al.
Wei Chen et al.
Active Surveillance for Complex Cystic Renal Masses: Individualization over Generalization [0.03%]
复杂囊性肾脏肿瘤的主动监测：个体化而非普遍化原则
Lorraine Scanlon,Brant A Inman
Lorraine Scanlon
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations [0.03%]
SWOG S2210二期临床试验：用于局部高危伴胚系BRCA1/2突变前列腺癌的新辅助卡铂治疗临床研究正在进行中
Heather H Cheng,Sam Callis,Evan Y Yu et al.
Heather H Cheng et al.
SWOG S2210 is a phase 2 trial testing the use of biomarker-guided neoadjuvant carboplatin, a safe and accessible chemotherapy agent, for patients with localized high-risk prostate cancer and inherited BRCA1/2 mutations. The endpoints are pa...
Neoadjuvant Systemic Therapy in High-risk Localised Prostate Cancer: Current Evidence and Future Directions [0.03%]
高危局限性前列腺癌的新辅助全身治疗：当前证据和未来方向
Abdullah Al-Khanaty,David Hennes,Marlon L Perera et al.
Abdullah Al-Khanaty et al.
High-risk localised and locally advanced prostate cancer (PC) accounts for nearly 25% of new PC diagnoses and is associated with significantly greater mortality in comparison to lower-risk disease. Radical prostatectomy (RP) remains central...
Exciting Times in Urological Oncology: Rapid Advances and Greater Complexity Are Changing Practice and Improving Outcomes [0.03%]
泌尿生殖系统肿瘤的精彩年代：迅速发展与日增复杂性正在改变实践并提高疗效
Shilpa Gupta,James W F Catto
Shilpa Gupta
Current Standard for High-risk Upper Tract Urothelial Cancer: Platinum-based Chemotherapy-Proven, Not Postulated [0.03%]
高危上尿路尿路上皮癌的铂类化疗标准应建立在证据之上，而不能是假设
Alison J Birtle
Alison J Birtle
Adjuvant chemotherapy is the standard of care for high-risk upper tract urothelial carcinoma after radical nephroureterectomy. Level 1 data and global guidelines confirm that this is the case, and adjuvant chemotherapy remains the option to...